DIGITALDX
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Rumi Yokota
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Erin Niehaus
      • Vivian Lu
      • Amit Goldman
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Michael Doherty
      • Laura Yecies
      • Jean Machart
      • Maria Millan
      • Renee Ryan
      • Laura Mezey
      • Barbara Levy
      • Ramin Khaksar
      • Alissa Hsu Lynch
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
      • Mrunalini Parvataneni
      • Doug Ross
      • Scott Ashworth
      • Richard Frank
      • Molly Martell
      • Drew Watson
      • Karim Refaey
      • Jennifer Quigley
      • Tracy I George
      • Elise Singer
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Macieira-Kaufmann
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
Picture
* Market Opportunity: Breast Cancer > $20B, 20m Mammograms/year in US, 15% result in "call backs"
​* Technology: Non-invasive saliva testing
* Management Team: Life Sciences Veterans. Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics


NEPHROSANT has a unique non-invasive urine diagnostic, with a proprietary urine life extender preservative, that gives accurate and actionable clinical results quickly, with a compact device and reader designed for point of care testing. Kidney injury is treatable, but usually asymptomatic until later stages and not reversible once it progresses to Stage 3. We invested in this company because the CEO is incredibly impressive and the test has the highest sensitivity/specificity (90’s), far exceeding CareDX & Natera, the market leaders. The company has potentially foundational patents in the kidney transplant space. The founder is a nationally recognized expert with her own lab at UCSF and can monetize under existing codes. She has also patented both her urine life extender and transplant rejection IP. In July 2019, the White House announced its focus on kidney disease. In August, Natera reached out to the company to start a dialogue. Stellar team and solid investment. (They also secured CLIA lab space with a strategy to accelerate the approval process.)
Disclaimer
Terms & Conditions
Privacy Policy
Investment Inquiries
Contact
Picture
Picture
Picture
 Copyright © 2025 All Rights Reserved
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Rumi Yokota
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Erin Niehaus
      • Vivian Lu
      • Amit Goldman
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Michael Doherty
      • Laura Yecies
      • Jean Machart
      • Maria Millan
      • Renee Ryan
      • Laura Mezey
      • Barbara Levy
      • Ramin Khaksar
      • Alissa Hsu Lynch
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
      • Mrunalini Parvataneni
      • Doug Ross
      • Scott Ashworth
      • Richard Frank
      • Molly Martell
      • Drew Watson
      • Karim Refaey
      • Jennifer Quigley
      • Tracy I George
      • Elise Singer
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Macieira-Kaufmann
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press